Rezolute (NASDAQ:RZLT) Given New $9.00 Price Target at JMP Securities

Rezolute (NASDAQ:RZLT) had its price objective boosted by analysts at JMP Securities from $8.00 to $9.00 in a report released on Thursday,Benzinga reports. The firm currently has a “market outperform” rating on the stock. JMP Securities’ price target indicates a potential upside of 95.23% from the stock’s current price.

A number of other equities analysts have also recently commented on RZLT. HC Wainwright reissued a “buy” rating and set a $14.00 price target on shares of Rezolute in a report on Wednesday, February 5th. Guggenheim reissued a “buy” rating on shares of Rezolute in a report on Monday, February 10th. Craig Hallum raised Rezolute to a “strong-buy” rating in a report on Tuesday, February 4th. Finally, Wedbush reissued an “outperform” rating and set a $112.00 price target on shares of Rezolute in a report on Monday, November 4th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Rezolute has an average rating of “Buy” and a consensus target price of $24.38.

Rezolute Price Performance

Shares of NASDAQ RZLT opened at $4.61 on Thursday. The stock has a market capitalization of $267.10 million, a PE ratio of -3.63 and a beta of 1.10. The business has a fifty day moving average price of $4.87 and a two-hundred day moving average price of $4.90. Rezolute has a fifty-two week low of $1.13 and a fifty-two week high of $6.19.

Rezolute (NASDAQ:RZLT) last announced its quarterly earnings data on Wednesday, February 12th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.11. On average, equities analysts expect that Rezolute will post -0.99 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Daron Evans bought 10,000 shares of the stock in a transaction on Wednesday, December 18th. The stock was acquired at an average price of $4.29 per share, with a total value of $42,900.00. Following the acquisition, the chief financial officer now directly owns 150,900 shares in the company, valued at approximately $647,361. This trade represents a 7.10 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 18.39% of the company’s stock.

Institutional Investors Weigh In On Rezolute

A number of institutional investors have recently made changes to their positions in the stock. Nantahala Capital Management LLC grew its position in shares of Rezolute by 10.9% in the 4th quarter. Nantahala Capital Management LLC now owns 2,857,982 shares of the company’s stock valued at $14,004,000 after buying an additional 280,861 shares during the last quarter. Oxford Asset Management LLP bought a new stake in shares of Rezolute in the 4th quarter valued at about $154,000. Adage Capital Partners GP L.L.C. grew its position in shares of Rezolute by 699.7% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,525,883 shares of the company’s stock valued at $12,377,000 after buying an additional 2,210,038 shares during the last quarter. Alpine Global Management LLC bought a new stake in shares of Rezolute in the 4th quarter valued at about $54,000. Finally, Susquehanna International Group LLP grew its position in shares of Rezolute by 749.0% in the 4th quarter. Susquehanna International Group LLP now owns 893,601 shares of the company’s stock valued at $4,379,000 after buying an additional 788,349 shares during the last quarter. Institutional investors own 82.97% of the company’s stock.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.